Brain+ logo

Om bolaget Analys Analytikerkommentar Video Textintervju

Brain+ A/S (“Brain+” or “the Company”) is a Digital Therapeutic company with the mission to restore patients’ independence and quality of life by treating and detecting cognitive decline in Alzheimer’s disease and dementia through Digital Therapeutics (DTx), also known as software-as-a-medicine (SaaM) applications. Brain+ has developed a set of DTx technologies, which enable the Company to create a unique and differentiated product offering. These technologies, combined with a strong clinical pipeline, puts Brain+ in a strong position to grow towards a market leader position in the dementia DTx space. Brain+ is listed on First North Copenhagen since October 7, 2021.


Tyvärr kan finansiell information för tillfället ej hämtas på detta bolag.